Bacterin International recently announced that the first clinical results using its OsteoSponge product for foot and ankle arthrodesis have been published in The Journal of Foot & Ankle Surgery, in an article reporting a multicenter, retrospective analysis of 80 joint fusions in 47 subjects who had experienced foot and ankle fusion procedures utilizing OsteoSponge bone graft. Radiographic analysis determined an overall fusion rate of 97.5% (78 out of 80 joints).
Entitled “A Retrospective Analysis Evaluating Allogeneic Cancellous Bone Sponge for Foot and Ankle Arthrodesis,” the article reported comparable or greater foot and ankle fusion rates, judged radiographically, to those reported in the biomedical literature. Also, the authors observed at the 12-month post-operative assessment that there were significant improvements in function and pain alleviation at rates greater than those reported previously in biomedical studies.
Serving as a further testament to the efficacy of the OsteoSponge product, the data published in The Journal of Foot and Ankle Surgery is anticipated to aid in the company’s goal of expanding its presence in the foot and ankle bone grafting market. The findings are also consistent with Bacterin’s mission to help its surgeon users provide their patients with the best possible clinical outcomes.
Bacterin International is a developer, manufacturer, and marketer of biologics products to domestic and international markets. The company’s proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold for promoting bone, subchondral repair, and dermal growth. The company’s products are utilized in various applications, including enhancing fusion in spine surgery, relieving back pain, promoting bone growth in foot and ankle surgery, promoting cranial healing after neurosurgery, and subchondral repair in knee and other joint surgeries. The company’s medical device division is engaged in developing, employing, and licensing bioactive coatings for a variety of medical device applications. Its strategic coating initiatives include antimicrobial coatings that are designed to inhibit biofilm formation and microbial contamination.
For more information, visit www.bacterin.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
